| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA766: Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma |
|
Medicine details |
|
| Medicine name | pembrolizumab (Keytruda®) |
| Formulation | concentrate for solution for infusion |
| Reference number | 2829 |
| Indication | As monotherapy for the adjuvant treatment of adults with Stage III melanoma and lymph node involvement who have undergone complete resection |
| Company | Merck Sharp & Dohme Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 07/02/2019 |
| NICE guidance | TA766: Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma |